Investor FAQs
Where is Kala Pharmaceuticals, Inc.'s corporate headquarters?
1167 Massachusetts Avenue,
Arlington, MA 02476
Arlington, MA 02476
Where is Kala Pharmaceuticals, Inc. incorporated?
Delaware
When did Kala Pharmaceuticals, Inc. go public?
Kala Pharmaceuticals went public on July 20, 2017
What is Kala Pharmaceuticals, Inc.’s fiscal year?
December 31
How is Kala Pharmaceuticals, Inc. stock traded?
Kala Pharmaceutical is traded on the NASDAQ Global Select Market under the symbol “KALA”
Does Kala Pharmaceuticals, Inc. pay dividends and have a dividend reinvestment program?
Currently, Kala Pharmaceuticals does not pay a dividend or offer a dividend reinvestment program
Who is Kala Pharmaceuticals, Inc.'s transfer agent?
American Stock Transfer & Trust Company, LLC.
How do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate?
Please contact our transfer agent, American Stock Transfer & Trust Company, LLC, at http://www.astfinancial.com/issuer-investor-services. American Stock Transfer & Trust Company can look up your records and make any necessary adjustments. There may be a fee involved for replacing lost certificates.
Does Kala Pharmaceuticals, Inc. have a direct stock purchase plan?
Kala Pharmaceuticals does not offer a direct stock purchase plan
How can I purchase shares?
Shares can be purchased through a stockbroker of your choice.
Who is Kala Pharmaceuticals, Inc.'s auditor?
Deloitte & Touche
Who is Kala Pharmaceuticals, Inc.'s legal counsel?
Wilmer Cutler Pickering Hale and Dorr LLP, Boston, Massachusetts
How many employees does Kala Pharmaceuticals, Inc. have?
Approximately 190 employees
Where can I get the latest corporate news releases?
You can view our recent press releases by visiting the Press Releases section of our website.
How can I view documents Kala Pharmaceuticals, Inc. has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?
Quarterly & Annual reports and other investor materials are available under SEC Filings of the Investors & Media section of our corporate website. Additionally, all SEC filings can be accessed directly from the SEC at www.sec.gov.
Who makes up the Kala Pharmaceuticals, Inc. Executive Management team and Board of Directors?
| Name | Position |
|---|---|
| Mark Iwicki | Chief Executive Officer and Chairman of the Board |
| Todd Bazemore | President & Chief Operating Officer |
| Kim Brazzell, Ph.D. | Head of R&D and Chief Medical Officer |
| Darius Kharabi | Chief Business Officer |
| Mary Reumuth, C.P.A. | Chief Financial Officer |
| Eric Trachtenberg | General Counsel and Chief Compliance Officer |
| Mark Blumenkranz | Director |
| Gregory Grunberg, M.D. | Director |
| Andrew Koven | Director |
| Robert Paull | Director |
| Greg Perry | Director |
| Howard Rosen | Director |
How can I sign up to receive Kala Pharmaceuticals’ press releases, email updates and other company information?
Please visit the Investors & Media section of our corporate website and choose the "Email Alerts" icon to be added to the Kala Pharmaceuticals distribution list
Whom should I contact regarding investor inquiries?
For investor related questions, please contact Hannah Deresiewicz at hannah.deresiewicz@sternir.com or via phone at +1-212-362-1200.
How can obtain a copy of your annual report and proxy?
SEC maintains an Internet website, which is located at http://www.sec.gov, that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.